Join
Live feed
·
PRReleasevia Quantisnow
AstraZeneca PLC logo

BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension

ByQuantisnow·Wall Street's wire, on your screen.
AZN· AstraZeneca PLC
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AZN (AstraZeneca PLC) and more on Quantisnow.